KdT Ventures is the standard in early-stage biotech investing. We help founders and their companies re-architect the world at a molecular level.
PathAI secures a $60M Series B from General Atlantic and General Catalyst
Solugen raises another $32M to continue disrupting the chemicals industry
54Gene is capturing the missing diversity in the human genome
StrideBio is a gene therapy company developing immune-evading viral vectors to expand the treatable patient population.
StrideBio executes $710M pact with Takeda to treat neurological disease
StrideBio closes oversubscribed $15.7M Series A with Takeda Ventures & others
StrideBio raises seed financing from Hatteras Venture Partners
StrideBio executes partnership deal with CRISPR Therapeutics and Casebia
"Phil started on the ground floor at StrideBio, helping us compile and evaluate a clinical pipeline that highlighted our technology's key strengths, and he has seen the evolution of these projects as they begin to come to life. His ability to synthesize scientific, commercial, and medical information provides invaluable input to our discussions."
Aravind Asokan, PhD
Ribometrix has proprietary methods to determine 3D RNA structures and develop structure-based drug screening.
Ribometrix inks strategic $700M collaboration with Vertex Pharmaceuticals
Ribometrix raises $30M Series A from Merck, Abbvie, Amgen, and Illumina
Ribometrix raises $7.5M seed from SV Health Investors, AbbVie, and others
"Phil was instrumental in identifying high-impact targets for our platform technology, and his work ultimately allowed us to establish the interest of and obtain a major funding commitment from our first strategic venture investor.
Phil played several critical roles during early stages of our start up, including honing pitches, developing a 5-year financial model, and identifying targets of broad interest to major investors. Phil's contributions categorically enabled us to land a multi-million-dollar seed investment."
Kevin Weeks, PhD
Company In Development
Information coming soon.